20 open trials dating back 180 days from clinicaltrials.gov: Novartis Nilotinib Compassionate Use (CU) Program Patients who are not able to participate in ongoing nilotinib clinical trials may be able to receive nilotinib on a compassionate use basis. Requests for compassionate use will only be considered when the request is sent to Novartis by the treating physician through a secure, business email. Patients will be evaluated for eligibility based on pre-defined inclusion/exclusion criteria. Requests should be routed to the local, country Novartis medical representative for submission to the following email address: Nilotinib.CompassionateUse@Novartis.com